Nature Biotechnology, Volume: 28 ,Pages: 1069–1078,Year published:(2010)
DOI:10.1038/nbt.1678, Published online 13 October 2010
Theresa K Kelly, Daniel D De Carvalho & Peter A Jones Departments of Urology and Biochemistry and Molecular Biology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
The paper focus on recent examples in which epigenetic modifications have been used to evaluate disease risk, progression and clinical response. It provide a broad overview of the accomplishments, remaining challenges and unrealized potential of epigenetic therapies in a range of diseases, with a particular emphasis on cancer.
FULL TEXT
Thursday, October 14, 2010
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment